SPAISAFE PRO GROUP INC.
Is Safe Pro Group struggling financially?
Yes, by its own account. Safe Pro Group told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
30/100
Fragile
- Sector
- Biotech/Pharma
- Market cap
- $109.3M
- Source filing
- 10-Q 15 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
8months
If the burn speeds up
Empty by Mar 2027
-
13months
If it eases off
Empty by Jul 2027
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$10.2M
÷
Cash burned over the last 12 months
$11.7M
What Safe Pro Group told the SEC
…21, 2025 and October 21, 2025 private placements of $ 8,000,000 and $ 14,000,000 , respectively, serve to mitigate the conditions that historically raised substantial doubt about the Company’s ability to continue as a going concern. The Company believes that the Company has sufficient cash to meet its obligations for a minimum of twelve months from the date of this filing. 5 SAFE PRO GROUP INC. AND SUBSIDIARIES…
SAFE PRO GROUP INC., Form 10-Q, filed 15 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- Cash burn is increasing It is spending 64% more cash per year than it was, so the runway above shortens even if nothing else changes.
- 37.3% share-count increase The company issued stock. Each share now owns 27.2% less of the business than a year ago, before any change in the price.
Other Biotech/Pharma companies that filed the doubt
- MTVA Metavia $9.6M
- EXOZ Exozymes $66.4M
- ATOS Atossa Therapeutics $25.3M
- CALC CalciMedica $19.6M
- ARMP Armata Pharmaceuticals $189.6M
- KOD Kodiak Sciences $2.4B